London, ON – March 6, 2019 – Stiris Research (“Stiris”) an entrepreneurial clinical trial management company focused on the management of Phase I-IIIB trials, today announce the successfully completion of their Phase I Zika virus trial.
“We are thankful to have had the opportunity to work on this exciting trial. We look forward to hearing the results of this trial, and that a potential treatment option for this infection is identified,” said Amanda Carrera, Vice President, Stiris Research Inc.
Zika virus is a mosquito-borne flavivirus that was first identified in Uganda in 1947 in monkeys. It was later identified in humans in 1952 in Uganda and the United Republic of Tanzania. Outbreaks of Zika virus disease have been recorded in Africa, the Americas, Asia and the Pacific from the 1960s to the 1980s, with rare and sporadic cases of human infections. In 2015, Brazil reported an association between Zika virus and microcephaly. Outbreaks and evidence of transmission soon appeared throughout the Americas, Africa and other regions around the world. To date, 86 countries and territories have reported evidence of mosquito-transmitted Zika infection (www.who.int).
About Stiris Research
Stiris Research is an entrepreneurial Clinical Trial Management company specializing in conducting complex Phase I through IIIB trials for North American biotechnology and biopharmaceutical companies, with a focus on Oncology, CNS and Neurology. Stiris Research was formed as a result of listening to the stakeholders engaged in clinical trials, identifying their unmet needs, and developing a unique, value-based approach to address those needs.